ARCHIVES

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

This article is from The Cancer Letter archive.

Vol. 26 No. 10 | October 31, 2003

Download PDF Visit The Full Archive

Related Articles

Atrix, Sanofi In Marketing Deal For Leuprogel Products.

January 26, 2001

FDA Likely To Change Procedures For Patient Interaction, Official Says

November 10, 1995

ACS Defends Dialogue, Calls Story “Misleading”.

October 20, 2000

FDA Advisors: DepoCyt May Test Accelerated Approval Mechanism

November 27, 1998

The March, Sept. 26: Events Planned In D.C., Around The U.S.

September 4, 1998

House Committee Gives NCI Only $6.5 Million Over President’s request

July 28, 1989